Cargando…

FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 M(pro) and PL(pro)

FlipGFP assay characterizes the intracellular drug target engagement to M(pro) and PL(pro) and can be performed in the biosafety level 1/2 settings. Here, we provide the detailed protocol for the cell-based FlipGFP assay to identify and characterize SARS-CoV-2 M(pro) and PL(pro) inhibitors. We descr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Haozhou, Hu, Yanmei, Wang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156985/ https://www.ncbi.nlm.nih.gov/pubmed/37329507 http://dx.doi.org/10.1016/j.xpro.2023.102323

Ejemplares similares

Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and FlipGFP-based reporter assay
por: Xia, Zilei, et al.
Publicado: (2021)

Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay
por: Ma, Chunlong, et al.
Publicado: (2021)

Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
por: Ma, Chunlong, et al.
Publicado: (2022)

Fluorogenic in vitro activity assay for the main protease M(pro) from SARS-CoV-2 and its adaptation to the identification of inhibitors
por: Ihssen, Julien, et al.
Publicado: (2021)

Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases
por: Jade, Dhananjay, et al.
Publicado: (2021)

Discovery of PL(pro) and M(pro) Inhibitors for SARS-CoV-2
por: Puhl, Ana C., et al.
Publicado: (2023)

Diphenyl Diselenide and SARS-CoV-2: in silico Exploration of the Mechanisms of Inhibition of Main Protease (M(pro)) and Papain-like Protease (PL(pro))
por: Omage, Folorunsho Bright, et al.
Publicado: (2023)

In Silico and In Vitro Inhibition of SARS-CoV-2 PL(pro) with Gramicidin D
por: Protić, Sara, et al.
Publicado: (2023)

MERS‐CoV papain-like protease (PL(pro)): expression, purification, and spectroscopic/thermodynamic characterization
por: Malik, Ajamaluddin, et al.
Publicado: (2017)

Computer-aided drug design for the pain-like protease (PL(pro)) inhibitors against SARS-CoV-2
por: Gao, Hongwei, et al.
Publicado: (2023)

Spatial and temporal roles of SARS‐CoV PL(pro)—A snapshot
por: Yan, Shaomin, et al.
Publicado: (2020)

SARS-CoV-PL(pro)-Inhibitoren als mögliche Breitspektrum-Virostatika
por: Hammerschmidt, Stefan Josef, et al.
Publicado: (2021)

Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PL(pro) and M(pro)/ 3CL(pro): molecular docking and simulation studies of three pertinent medicinal plant natural components
por: Verma, Devvret, et al.
Publicado: (2021)

Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PL(pro) and M(pro) proteases, and nsp14 guanine N7-methyltransferase
por: Zmudzinski, Mikolaj, et al.
Publicado: (2023)

Development of 2-chloroquinoline based heterocyclic frameworks as dual inhibitors of SARS-CoV-2 M(Pro) and PL(Pro)
por: Kattula, Bhavita, et al.
Publicado: (2023)

Effects of diarylbutane lignans from Schisandra chinensis fruit on SARS-CoV-2 3CL(pro) and PL(pro) and their in vitro anti-inflammatory properties
por: Li, Bin, et al.
Publicado: (2023)

Fluorine Atoms on C(6)H(5)-Corrole Affect the Interaction with M(pro) and PL(pro) Proteases of SARS-CoV-2: Molecular Docking and 2D-QSAR Approaches
por: Chaves, Otávio Augusto, et al.
Publicado: (2022)

Potential COVID-19 papain-like protease PL(pro) inhibitors: repurposing FDA-approved drugs
por: Kouznetsova, Valentina L., et al.
Publicado: (2020)

An overview of potential inhibitors targeting non-structural proteins 3 (PL(pro) and Mac1) and 5 (3CL(pro)/M(pro)) of SARS-CoV-2
por: Yan, Fangfang, et al.
Publicado: (2021)

Protocol for production and purification of SARS-CoV-2 3CL(pro)
por: Mazzei, Luca, et al.
Publicado: (2023)

Metallodrug Profiling against SARS‐CoV‐2 Target Proteins Identifies Highly Potent Inhibitors of the S/ACE2 interaction and the Papain‐like Protease PL(pro)
por: Gil‐Moles, Maria, et al.
Publicado: (2021)

Dual targeting of 3CL(pro) and PL(pro) of SARS-CoV-2: A novel structure-based design approach to treat COVID-19
por: Rajpoot, Sajjan, et al.
Publicado: (2020)

“Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL(pro) and PL(pro)"
por: Bhowmik, Deep, et al.
Publicado: (2021)

In silico studies of M(pro) and PL(pro) from SARS-CoV-2 and a new class of cephalosporin drugs containing 1,2,4-thiadiazole
por: Delgado, Cássia Pereira, et al.
Publicado: (2022)

Schaftoside inhibits 3CL(pro) and PL(pro) of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19
por: Yi, Yang, et al.
Publicado: (2022)

Inhibitory effects of selected isoquinoline alkaloids against main protease (M(pro)) of SARS-CoV-2, in silico study
por: Sadeghi, Morteza, et al.
Publicado: (2022)

Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL(pro) and PL(pro)), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2)
por: Mouffouk, Chaima, et al.
Publicado: (2021)

Protocol for in vitro fluorescence assay of papain-like protease and cell-based immunofluorescence assay of coronavirus infection
por: Chang, JuOae, et al.
Publicado: (2023)

A yeast-based system to study SARS-CoV-2 M(pro) structure and to identify nirmatrelvir resistant mutations
por: Ou, Jin, et al.
Publicado: (2022)

A yeast-based system to study SARS-CoV-2 M(pro) structure and to identify nirmatrelvir resistant mutations
por: Ou, Jin, et al.
Publicado: (2022)

Structural Insight into the Binding of Cyanovirin-N with the Spike Glycoprotein, M(pro) and PL(pro) of SARS-CoV-2: Protein–Protein Interactions, Dynamics Simulations and Free Energy Calculations
por: Naidoo, Devashan, et al.
Publicado: (2021)

In silico study of natural compounds from sesame against COVID-19 by targeting M(pro), PL(pro) and RdRp
por: Allam, Ahmed E., et al.
Publicado: (2021)

Protocol for in vitro analysis of pro-inflammatory and metabolic functions of cultured primary murine astrocytes
por: Gutiérrez-Vázquez, Cristina, et al.
Publicado: (2021)

Polyphenolic Compounds Isolated from Marine Algae Attenuate the Replication of SARS-CoV-2 in the Host Cell through a Multi-Target Approach of 3CL(pro) and PL(pro)
por: Nagahawatta, D. P., et al.
Publicado: (2022)

Virtual screening based on the structure of more than 10(5) compounds against four key proteins of SARS-CoV-2: M(Pro), S(RBD), RdRp, and PL(pro)
por: Nabati, Farzan, et al.
Publicado: (2022)

In silico analysis of echinocandins binding to the main proteases of coronaviruses PEDV (3CL(pro)) and SARS-CoV-2 (M(pro))
por: Vergoten, Gérard, et al.
Publicado: (2021)

Pro-resolving and anti-arthritic properties of the MC(1) selective agonist PL8177
por: Garrido-Mesa, Jose, et al.
Publicado: (2022)

A yeast-based system to study SARS-CoV-2 M(pro) structure and to identify nirmatrelvir resistant mutations
por: Ou, Jin, et al.
Publicado: (2023)

Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor
por: Tan, Haozhou, et al.
Publicado: (2022)

Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor
por: Tan, Haozhou, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ulv698hjs4fbi7cj5a364lhfv2